Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Delayed Quote. Delayed  - 07/29 10:00:16 pm
125.23 USD   +0.62%
07/30 JOHNSON & JOHNS : Operation Family Caregiver Expands to Washington S..
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJExperimental Alzheimer's Drug Fails in Trial
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J in $4 Billion Settlement Talks

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/12/2013 | 11:16pm CEST

Johnson & Johnson (JNJ) has agreed to pay $4 billion to settle more than 7,500 lawsuits over the company's recalled hip-implant products, Bloomberg News reported Tuesday, citing three people familiar with the agreement.

The settlement will be announced next week, Bloomberg reported.

Full story at: www.bloomberg.com/news/2013-11-12/j-j-said-to-reach-4-billion-deal-to-settle-hip- awsuits.html

Write to nymonitoring@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
07/30 JOHNSON & JOHNSON : Operation Family Caregiver Expands to Washington State and N..
07/29 JOHNSON & JOHNSON : Operation Family Caregiver Expands to Washington State and N..
07/28 Johnson & Johnson Reports 2016 Second-Quarter Results
07/28 JOHNSON & JOHNSON : RefleXion Medical Extends Series B Financing to $52 Million ..
07/28 Weak China sales drag down Smith & Nephew profits
07/27DJExperimental Alzheimer's Drug Fails in Trial
07/27 GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/26 JOHNSON & JOHNSON : Janssen Announces Clinical Collaboration with Bristol-Myers ..
07/26 JOHNSON & JOHNSON : Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designa..
07/26 JOHNSON & JOHNSON : J&J reports progress on anti-HIV vaccine
More news
Sector news : Pharmaceuticals - NEC
07/30DJMERCK : Earnings Watch -- WSJ
07/30 BAYER : says will halt future U.S. sales of insecticide
07/29DJTech Stocks Up On Google Earnings - Tech Roundup
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments -- Update
07/29DJABBVIE : Results Boosted by Humira, Pipeline Growth
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/30 LANCASTER COLONY : A Dividend King With 53 Years Of Dividend Increases (Part 13 ..
07/30 RESURGENCE OF LANNETT : A Growing Opportunity
07/30 VistaGen Is An Interesting Opportunity, Following Allergan's Anti-Depressant ..
07/28 Guest Charles Gooch, Jr. (Part 2) - Dividend Health Checkup Podcast - Episode..
07/27 Johnson & Johnson Delivers Strong Results
Advertisement
Financials ($)
Sales 2016 72 078 M
EBIT 2016 21 811 M
Net income 2016 16 515 M
Finance 2016 13 414 M
Yield 2016 2,51%
P/E ratio 2016 21,28
P/E ratio 2017 18,83
EV / Sales 2016 4,59x
EV / Sales 2017 4,29x
Capitalization 344 463 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 0,93%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON21.91%344 463
PFIZER INC.14.28%223 732
ROCHE HOLDING LTD.-9.99%218 231
NOVARTIS AG-5.30%215 109
MERCK & CO., INC.11.06%162 372
BRISTOL-MYERS SQUIBB C..8.75%124 997
More Results